Navigation Links
Genmab Announces Year End 2007 Financial Results
Date:3/31/2008

venues in 2008, we are projecting an operating loss of DKK 900 to 1,000 million compared to the DKK 437 million reported for 2007. Under the conditions described above, the net loss for 2008 is expected to be in the range of DKK 800 to 900 million compared to the net loss of DKK 383 million reported for 2007.

As of December 31, 2007, Genmab had cash, cash equivalents and short-term marketable securities of DKK 3.7 billion (approximately USD 728 million). We expect the 2008 cash burn to consist of USD 240 million (approximately DKK 1.2 billion) paid for the acquisition of the manufacturing facility, operational expenses of approximately DKK 750-800 million (approximately USD 148-158 million) and approximately DKK 40-50 million (approximately USD 8-10 million) in other capital expenditures. We expect to spend over 90% of our 2008 budget on research and development, including the operation of our manufacturing facility and less than 10% on general and administrative expenses. Of the research and development costs, we expect to spend approximately DKK 500 million (approximately USD 98 million) on development for the ofatumumab program.

Total projected revenues for 2008 are expected to be approximately DKK 1.0 billion (approximately USD 197 million), an increase of approximately DKK 470 million (approximately USD 93 million) over 2007 revenues, which were 530 million (approximately USD 104 million). Net financial income is expected to be approximately DKK 70-75 million (approximately USD 14-15 million). Thus, including the manufacturing acquisition and operational expenses, we are projecting a 2008 year end cash position of DKK 1.7 to 1.8 billion (approximately USD 335 to 355 million).

The estimates above are subject to possible change primarily due to the timing and variation of development activities, related income and costs and fluctuating exchange rates. Our projected 2008 revenues consist primarily of milestone payments, for which we cannot alw
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Shimadzu Scientific ... Chromatograph (2D-LC), which offers a powerful separation ... The system provides a new level of ... is beneficial to scientists analyzing pharmaceutical impurities, ... products. , Comprehensive 2D-LC combines two independent ...
(Date:9/17/2014)... , Sept. 17, 2014 BioClinica®, Inc., ... eClinical Solutions, today announced three of its experts are ... for Clinical Data Management to be held September 28 ... . The Company also announced the innovative ... overall quality in clinical trials acquired earlier this year, ...
(Date:9/17/2014)... Hussey Copper , a leader in ... copper, announces Gilmour Academy Ice Arena,s conversion of more ... solid touch surface to help protect against bacteria.  MD-Cu ... that kills greater than 99.9% of MRSA, E-coli and ... , Innovative Gilmour Academy ...
(Date:9/17/2014)... RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... has been granted a patent by the United ... delivery system for delivering its "original" RNAi compounds ... treatment of diseases with an inflammatory component. Potential ...
Breaking Biology Technology:Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... 25 Scimitar Equity, LLC issues a ... VOQP), entitled,"Creating Value; Turnaround Leverages Product Opportunities ... review is available at website: http://www.scimitarequity.com ... Jersey-based biotechnology company,dedicated to becoming a recognized ...
... 25 Mymetics,Corporation (OTC: MYMX), will be holding an ... PM New York Time to update all shareholders,on the ... Form 10-Q and to,address recent press articles., You ... at +1-866-591-4361 PIN 815,726 and from Europe at +41-800-329-326 ...
... 23 Eisai Corporation of,North America and its ... Food and Drug Administration (FDA) has approved a ... prevention of,chemotherapy-induced nausea and vomiting (CINV). ALOXI Capsules ... prevention of acute nausea and,vomiting following initial and ...
Cached Biology Technology:VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC 2FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting 2FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting 3
(Date:9/16/2014)... The 36 Pit Fire began on September 13, 2014. ... It is currently over 2,300 acres in size and ... The 36 Pit Fire was calm Monday night due to ... establishing an anchor point and beginning to construct a fireline ... The following resources are working on the fire: , 7 ...
(Date:9/16/2014)... same viruses that make us sick can take up ... a sneeze, cough or other troublesome symptom, according to ... St. Louis. , On average, healthy individuals carry ... researchers report online in BioMed Central Biology . ... the diversity of viruses in healthy people. , ...
(Date:9/16/2014)... for the dinosaurs 66 million years ago decimated the ... extent than their deciduous peers, according to a study ... the journal PLOS Biology . , Applying ... fossilized leaves of angiosperms flowering plants excluding ... ecology of a diverse plant community thriving during a ...
Breaking Biology News(10 mins):Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4
... percent as compared to last year,s record size. According to measurements ... 27.7 million tonnes, compared to the 2006 record ozone loss of ... area and the depth of the ozone hole. The area of ... 220 Dobson Units is 24.7 million sq km, roughly the ...
... vaccine delivered through painless microneedles in patches applied ... to delivery through hypodermic needles, according to researchers ... Technology. Using new grants from the National Institutes ... five years, researchers from the two institutions plan ...
... help may be on the way for beleaguered growers ... Many varieties of the widely grown bottlegourd (Lagenaria siceraria) ... (ZYMV), a scourge of commercial cucurbits that includes pumpkins, ... ZYMV infects cucurbits throughout North America and in other ...
Cached Biology News:2007 ozone hole 'smaller than usual' 22007 ozone hole 'smaller than usual' 3Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants 2Battling virus disease of watermelon with bottlegourds 2
HOXC11 Antibody...
HOXC11 Antibody...
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Biology Products: